Drug Type Polypeptide antibiotic |
Synonyms Antimicrobial Peptides PL-5, 培西加南, 抗菌肽PL-5 + [2] |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC138H226N36O34 |
InChIKeyIUYWAZJIRQDBEJ-XECNVCPKSA-N |
CAS Registry850761-47-6 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Infectious Diseases | NDA/BLA | China | 24 Dec 2024 | |
| Wound Infection | Phase 3 | China | 23 Aug 2021 | |
| Diabetic foot infection | Phase 2 | United States | 30 Jan 2024 | |
| Diabetic foot ulcer | Phase 2 | United States | 30 Jan 2024 | |
| Bacterial Infections | Phase 2 | United States | 11 May 2023 | |
| Secondary infection | Phase 2 | China | 28 Jul 2020 | |
| Post-traumatic wound infection | Phase 2 | China | 24 Jul 2018 | |
| Burn infections | Phase 1 | China | 07 Nov 2016 | |
| Diabetic Foot | Phase 1 | China | 07 Nov 2016 | |
| Folliculitis | Phase 1 | China | 07 Nov 2016 |
ADA2024 Manual | Not Applicable | 47 | jocppikvzq(xodpysdwph) = lxdbxptdow gyfmgrunrg (dqvpqrsgvk ) View more | Positive | 21 Jun 2024 | ||
Placebo | jocppikvzq(xodpysdwph) = xeyylxixcq gyfmgrunrg (dqvpqrsgvk ) View more | ||||||
| - | - | 570 | hnzfjkudmz(mcijeolvea) = lakchovlvq jxwkedahle (svsxclqjcq ) View more | Non-inferior | 03 Jun 2024 | ||
hnzfjkudmz(mcijeolvea) = kqxtbovcjk jxwkedahle (svsxclqjcq ) View more |





